Small Molecules, Biologics, Vaccines, The pipeline is comprised of antibody-based therapies and other protein-based therapeutics that modulate the immune system or directly target tumors.
Designing next generation immunotherapies based on gene-edited CAR T-cells
Develops technology to activate the innate and adaptive arms of the immune system to recognize and ultimately destroy tumor cells.
A private, non-profit, regional health care system.
CisThera’s mission is to develop innovative therapeutics to treat cancer, autoimmune diseases, as well as chronic kidney and liver diseases.
Develops molecules to activate Toll like receptors. These can be used to stimulate the innate immune system.
Codiak plans to define and engineer exosomes with single or multiple payloads directed against specific intracellular targets.
Compliment Corporation is a start-up biotechnology company developing revolutionary therapeutics in oncology. Our mission is to improve cancer treatment by dramatically increasing the ...
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel agents that target the immune system to treat patients with cancer.
CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers
Cullinan Oncology develops high value therapeutics geared towards dramatically improving the standard of care for those living with cancer.
Develops anti-cancer drugs.
Curtana Pharmaceuticals is developing highly targeted therapies for the treatment of brain cancer, including glioblastoma in adults and pediatric high grade glioma in children.
CytImmune’s nanotherapy platform, Aurimune, is a tumor-targeted Trojan horse. Aurimune selectively binds TNF receptors on blood vessel cells at the site of disease. Once bound, Aurimune unleashes ...
Develops cancer immunotherapies, drug conjugates (PDCs), T-cell engaging Probody bispecifics and ProCAR-NK cell therapies based on Protease-Activated Antibodies, 'Probodies'
Their technology identifies small sets of “master regulator” proteins, whose activity is critical for tumor survival (i.e. tumor-dependencies).
Immunotherapy treatment for prostate cancer.
DesignerRx produces novel protein therapeutics to treat cancer and other debilitating diseases in humans.
Makes a non-invasive device for cancer treatment. The device emits a low-level, non-thermal, non-ionizing radio frequency energy (RFE) for disrupting cell division in cancer.
Semi stealth mode - but has $42M investment
Focused on therapies for cancer and inflammatory diseases
Activating the immune system to eradicate cancer. Focuses on regulatory T cells.
Committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity.
Research and development programs currently focus on potential treatments in HIV/AIDS, liver diseases, hematology and oncology, inflammatory and respiratory diseases, and cardiovascular conditions ...
GO Therapeutics identifies sites of O-linked glycosylation on a wide range of proteins targets. The accessibility of these O-glycans at the plasma membrane is used to develop novel “hybrid” ...
Develops anti-cancer immunotherapies
Grid Therapeutics is an emerging biotechnology company located in Durham, North Carolina. Grid’s research and development efforts are in the area of cancer therapeutics, applying an innovative ...
Developing therapies to kill dormant disseminated tumor cell (DTC’s). DTCs are a leading cause of remission.
Advancing first-in-class immunotherapy product candidates in oncology, as well as infectious and allergic diseases.
Immune-Onc’s lead program, an antibody targeting an immune inhibitory receptor, is being explored as a potential candidate in the treatment of acute myeloid leukemia (AML) and other cancers.
Immunomedics has developed an antibody drug conjugate to treat women with triple-negative breast cancer.